Due to the role of in NRF2 in mediating oxidative stress response and the production of reactive oxygen species (ROS), both considered mediators of drug resistance and metastasis in cancer [48, 49], the use of antioxidant supplements, enzymes, and inhibitors for ROS-generating NADPH oxidases (NOX) could be a logical therapeutic intervention for AML patients with these particular genetic abnormalities. Here, FMO5 is linked to cancer.